Should you buy adaptimmune Therapeutics (ADAP)?

Graig Suvannavejh, an analyst from Mizuho Securities, reiterated the Buy rating on Adaptimmune Therapeutics ( ADAP – Research Report ). The associated price target remains the same with $3.00. Graig Suvannavejh has given his Buy rating due to a combination of factors that signal strong potential for Adaptimmune Therapeutics.

What is the price target for adaptimmune Therapeutics plc - depositary receipt ()?

As of May 22, 2024, the average one-year price target for Adaptimmune Therapeutics plc - Depositary Receipt () is 2.55. The forecasts range from a low of 1.01 to a high of $4.20. The average price target represents an increase of 152.48% from its latest reported closing price of 1.01.

Why has Graig suvannavejh rated adaptimmune Therapeutics a buy?

Graig Suvannavejh has given his Buy rating due to a combination of factors that signal strong potential for Adaptimmune Therapeutics. Key among these is the recently announced partnership with Galapagos for the development of uza-cel, a T-cell therapy targeting MAGE-A4, which is poised to treat ovarian cancer and potentially other solid tumors.